Publicacións en colaboración con investigadores/as de Fundación Jiménez Díaz (189)

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

  2. Correction to: Exploring the potential of Chat-GPT as a supportive tool for sialendoscopy clinical decision making and patient information support (European Archives of Oto-Rhino-Laryngology, (2024), 281, 4, (2081-2086), 10.1007/s00405-023-08104-8)

    European Archives of Oto-Rhino-Laryngology

  3. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  4. Executive summary of the consensus document on the management of perioperative anemia in Spain

    Revista Clinica Espanola, Vol. 224, Núm. 4, pp. 225-232

  5. Exploring the potential of Chat-GPT as a supportive tool for sialendoscopy clinical decision making and patient information support

    European Archives of Oto-Rhino-Laryngology, Vol. 281, Núm. 4, pp. 2081-2086

  6. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  7. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria

    Respiratory Medicine, Vol. 226

2023

  1. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  2. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 11, pp. 3407-3413.e1

  3. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  4. Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

    Cancers, Vol. 15, Núm. 17

  5. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 223-231

  6. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

    British Journal of Haematology, Vol. 203, Núm. 5, pp. 860-871

  7. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti–IL-5 Biologics: A Real-Life Study

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 1, pp. 37-44

  8. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 294-296

  9. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

  10. Reply to “Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies”

    Journal of Investigational Allergology and Clinical Immunology

  11. Residual pulmonary infiltrates, symptoms and diffusion impairment at 1-year after severe COVID-19 infection have different associated factors

    Journal of Internal Medicine, Vol. 294, Núm. 1, pp. 69-82

  12. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 608-611

2022

  1. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192